A registrational safety trial of transdermal zolmitriptan in patiens with migraine

Trial Profile

A registrational safety trial of transdermal zolmitriptan in patiens with migraine

Planning
Phase of Trial: Phase III

Latest Information Update: 26 Jun 2017

At a glance

  • Drugs Zolmitriptan (Primary)
  • Indications Migraine
  • Focus Adverse reactions; Registrational
  • Sponsors Zosano Pharma
  • Most Recent Events

    • 26 Jun 2017 According to a Zosano Pharma media release, the company anticipates initiating this trial in the third quarter of 2017.
    • 26 Jun 2017 According to a Zosano Pharma media release, the US FDA confirmed the design of this Long-term Safety Study as sufficient to support an NDA filing for M207.
    • 06 Mar 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top